BOOM

Trending Searches

    SUPPORT
    BOOM

    Trending News

      • Fact Check 
        • Fast Check
        • Politics
        • Business
        • Entertainment
        • Social
        • Sports
        • World
      • Law
      • Explainers
      • News 
        • All News
      • Decode 
        • Impact
        • Scamcheck
        • Life
        • Voices
      • Media Buddhi 
        • Digital Buddhi
        • Senior Citizens
        • Videos
      • Web Stories
      • BOOM Research
      • BOOM Labs
      • Deepfake Tracker
      • Videos 
        • Facts Neeti
      • Home-icon
        Home
      • About Us-icon
        About Us
      • Authors-icon
        Authors
      • Team-icon
        Team
      • Careers-icon
        Careers
      • Internship-icon
        Internship
      • Contact Us-icon
        Contact Us
      • Methodology-icon
        Methodology
      • Correction Policy-icon
        Correction Policy
      • Non-Partnership Policy-icon
        Non-Partnership Policy
      • Cookie Policy-icon
        Cookie Policy
      • Grievance Redressal-icon
        Grievance Redressal
      • Republishing Guidelines-icon
        Republishing Guidelines
      • Fact Check-icon
        Fact Check
        Fast Check
        Politics
        Business
        Entertainment
        Social
        Sports
        World
      • Law-icon
        Law
      • Explainers-icon
        Explainers
      • News-icon
        News
        All News
      • Decode-icon
        Decode
        Impact
        Scamcheck
        Life
        Voices
      • Media Buddhi-icon
        Media Buddhi
        Digital Buddhi
        Senior Citizens
        Videos
      • Web Stories-icon
        Web Stories
      • BOOM Research-icon
        BOOM Research
      • BOOM Labs-icon
        BOOM Labs
      • Deepfake Tracker-icon
        Deepfake Tracker
      • Videos-icon
        Videos
        Facts Neeti
      Trending Tags
      TRENDING
      • #Operation Sindoor
      • #Pahalgam Terror Attack
      • #Narendra Modi
      • #Rahul Gandhi
      • #Waqf Amendment Bill
      • #Arvind Kejriwal
      • #Deepfake
      • #Artificial Intelligence
      • Home
      • Coronavirus
      • DCGI Approves Moderna Vaccine,...
      Coronavirus

      DCGI Approves Moderna Vaccine, Cipla To Import

      The mRNA vaccine has shown over 90 per cent efficacy against SARS-CoV-2 and is also a part of the Covax agreement

      By - Shachi Sutaria |
      Published -  29 Jun 2021 8:15 PM IST
    • Boomlive
      DCGI Approves Moderna Vaccine, Cipla To Import

      The Drugs Controller General of India (DCGI) allowed Indian pharmaceutical Cipla to import the Moderna mRNA Covid-19 vaccine on Tuesday making it the fourth vaccine that will be available to Indians.

      Cipla will not have to conduct a bridging clinical trial as per the rules shared by the Ministry on June 1, 2021. Vaccines approved by the US Food and Drug Administration, the Pharmaceuticals and Medical Devices (PMDA) of Japan, the European Medicines Agency (EMA), or the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom are exempt from conducting trials as per the new notification.

      While Dr. Vinod Paul, member of Niti Aayog did not elaborate about the deal and doses in the weekly Ministry COVID-19 press conference, Cipla later in the evening released its official statement saying that they are only importing the vaccines that US is donating to India.

      "Cipla Limited is supporting Moderna, Inc. with the regulatory approval and importation of vaccines to be donated to India. At this stage, there is no definitive agreement on commercial supplies," read the statement.

      Cipla will be expected to perform a seven-day safety assessment through a thorough follow up of the first 100 recipients of the Moderna vaccine. Positive efficacy, immunogenicity, and safety results among these recipients will then be followed by the vaccine receiving approval to be administered to all the citizens of the country.

      Moderna vaccine has been approved as a New Drug Permission for Restricted Used under the New Drugs and Clinical Trial Rules , 2019 under Drugs and Cosmetics Act, 1940.

      Also Read:Has Moderna's Boss Said That Vaccines Can Alter Human DNA? A FactCheck

      Moderna: Storage And Efficacy

      Moderna's Covid-19 vaccine mRNA-1273, sold under the brand name 'Spikevax' in the United States, was developed by the pharmaceutical company in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA) in the US.

      Moderna's mRNA vaccine was found to be over 90 per cent effective against SARS-CoV-2. With a requirement of storage between -25ºC and -15ºC, Cipla will have to make special arrangements to ensure that the vaccine can survive in India's climate.

      Paul added that while Cipla will now be importing ready to inject vaccines, it may later try for its production. PTI reported that Cipla was willing to pay over $1 billion as advance to the US major for importing about 50 million doses.

      Also Read:Foreign Videos Of Empty Covid-19 Vaccine Shots Administered Viral In India

      (Note: This story has been updated with Cipla's official statement)

      Tags

      COVID-19moderna vaccine
      Read Full Article
      Next Story
      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker. Please reload after ad blocker is disabled.
      X

      Subscribe to BOOM Newsletters

      👉 No spam, no paywall — but verified insights.

      Please enter a Email Address
      Subscribe for free!

      Stay Ahead of Misinformation!

      Please enter a Email Address
      Subscribe Now🛡️ 100% Privacy Protected | No Spam, Just Facts
      By subscribing, you agree with the Terms & conditions and Privacy Policy connected to the offer

      Thank you for subscribing!

      You’re now part of the BOOM community.

      Or, Subscribe to receive latest news via email
      Subscribed Successfully...
      Copy HTMLHTML is copied!
      There's no data to copy!